12-month outcomes of dolutegravir (DTG) plus lamivudine (3TC) in ART-naive and pre-treated people living with HIV in Germany: real-world data from the German URBAN cohort

被引：0
|
作者：
Scholten, S. [1 ]
Noe, S. [2 ]
Wyen, C. [3 ]
Beer, D. [4 ]
Postel, N. [5 ]
Degen, O. [6 ]
Pauli, R. [7 ]
Hillenbrand, H. [8 ]
Westermayer, B. [9 ]
Dymek, K. M. [10 ]
Scherzer, J. [10 ]
机构：
[1] Praxis Hohenstaufenring, Cologne, Germany
[2] MVZ Munchen Goetheplatz, Munich, Germany
[3] Praxis Ebertplatz, Cologne, Germany
[4] Praxis Dr Knechten, Aachen, Germany
[5] Prinzmed, Munich, Germany
[6] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany
[7] MVZ Isartor, Munich, Germany
[8] MVZ PraxisCityOst, Berlin, Germany
[9] GlaxoSmithKline, Munich, Germany
[10] ViiV Healthcare, Munich, Germany
来源：
HIV MEDICINE | 2021年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
PE2/52
引用
收藏
页码：111 / 112
页数：2
相关论文
共 17 条
  • [1] Two-year outcomes of dolutegravir (DTG) plus lamivudine (3TC) in ART-naive and pre-treated people living with HIV in Germany: real-world data from the German URBAN cohort
    Beer, D.
    Scherzer, J.
    Noe, S.
    Scholten, S.
    Wyen, C.
    Postel, N.
    Degen, O.
    Sabranski, M.
    Westermayer, B.
    Dymek, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 112 - 113
  • [2] Real-world data from the prospective URBAN cohort study on the use of dolutegravir (DTG) plus lamivudine (3TC) in ART-naive and pre-treated people living with HIV in Germany
    Postel, N.
    Schneeweiss, S.
    Wyen, C.
    Schabaz, F.
    Degen, O.
    Weinberg, G.
    Sabranski, M.
    Ummard-Berger, K.
    Dymek, K.
    Westermayer, B.
    Scherzer, J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 48 - 49
  • [3] 2-Year outcomes of dolutegravir plus lamivudine in ART-naive and pre-treated people living with HIV in Germany: Real-world Data From the URBAN Cohort
    Beer, Daniel
    Scherzer, Jenny
    Noe, Sebastian
    Scholten, Stefan
    Wyen, Christoph
    Postel, Nils
    Degen, Olaf
    Sabranski, Michael
    Westermayer, Bernd
    Dymek, Kathrin M.
    Baum, Alexander
    HIV MEDICINE, 2023, 24 : 28 - 30
  • [4] Three-year outcomes for Dolutegravir (DTG) plus Lamivudine (3TC) in ARTnaive and pre-treated people living with HIV-1 (PLHIV) in Germany: Real-world data from the German URBAN cohort
    Noe, S.
    Scholten, S.
    Wyen, C.
    Sabranski, M.
    Postel, N.
    Degen, O.
    Beer, D.
    Ummard-Berger, K.
    Westermayer, B.
    Dymek, K. M.
    Scherzer, J.
    HIV MEDICINE, 2023, 24 : 137 - 139
  • [5] 48-Week effectiveness and tolerability of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral-naive adults living with HIV: A multicenter real-life cohort
    Cabello-Ubeda, Alfonso
    Bernardo de Quiros, Juan Carlos Lopez
    Martin Carbonero, Luz
    Sanz, Jesus
    Vergas, Jorge
    Mena, Alvaro
    Torralba, Miguel
    Hernandez Segurado, Marta
    Pinto, Adriana
    Tejerina, Francisco
    Palmier, Esmeralda
    Gutierrez, Angela
    Vazquez, Pilar
    Pulido, Federico
    Gorgolas, Miguel
    PLOS ONE, 2022, 17 (11):
  • [6] Real-world data from the prospective, multicentre study on the use of dolutegravir-based regimens (DBRs) in ART-naive and experienced people living with HIV: 12-month results from the Russian TESLA study
    Kuznetsov, S.
    Minaeva, S.
    Sizova, N.
    Nagimova, F.
    Orlova-Morozova, E.
    Radzikhovskaya, M.
    Shevchenko, V.
    Maldonado, A.
    Jones, B.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 82 - 83
  • [7] Real world data of using Triumeq (dolutegravir/abacavir/lamivudine; DTG/ABC/3TC): final outcomes of the 3-year German TRIUMPH cohort show good virologic effectiveness and safety in clinical routine
    Postel, N.
    Heuchel, T.
    Malfertheiner, P.
    Brust, J.
    Scholten, S.
    Stephan, C.
    Bohr, U.
    Hillenbrand, H.
    Lutz, T.
    Glaunsinger, T.
    Westermayer, B.
    Lueftenegger, D.
    Walli, R-K
    HIV MEDICINE, 2019, 20 : 81 - 82
  • [8] Characteristics and real-world medication persistence of people living with HIV treated with DTG/3TC or BIC/FTC/TAF: a hospital claims database study in Japan
    Kanamori, Rie
    Aoki, Nozomi
    Kanazawa, Akio
    Nakamoto, Daisuke
    Yuda, Mayumi
    Makino, Nao
    Ohata, Emi
    Fukui, Nobuyuki
    Mori, Hirotake
    Yokokawa, Hirohide
    Naito, Toshio
    FRONTIERS IN MEDICINE, 2024, 11
  • [9] Treatment-emergent integrase strand transfer inhibitor (INSTI) resistance-associated mutations among people living with HIV-1 treated with dolutegravir (DTG) plus lamivudine (3TC) with pre-existing M184V/I from real-world and interventional studies
    Fox, Dainielle
    Blick, Gary
    Mesplede, Thibault
    Verdier, Gustavo
    Calderon, Monica
    Parry, Chris M.
    Grove, Richard
    Letang, Emilio
    Priest, Julie
    Jones, Bryn
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 291 - 292
  • [10] Two-year long-term data on the efficacy and tolerability of dolutegravir-based regimens from the prospective multi-centre TESLA cohort study in ART-naive and pre-treated people living with HIV in Russia
    Basova, Anna
    Minaeva, Stella
    Sizova, Natalia
    Nagimova, Firaya
    Orlova-Morozova, Elena
    Radzikhovskaya, Margarita
    Shevchenko, Valeriy
    Maldonado-Doblado, Andres
    Jones, Bryn
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 103 - 105
12